MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Treating Glaucoma Early

Back to ophthalmology news Blogs list Cancer blog  


Subscribe To Ophthalmology News RSS Feed  RSS content feed What is RSS feed?






Treating Glaucoma Early

Treating Glaucoma Early
Treatments that delay the progression of glaucoma may significantly reduce the economic health burden on people with the disease and on the U.S. health system, according to a new study by scientists at Duke University Eye Center and elsewhere. Their findings appear in the January 9, 2006, issue of Archives of Ophthalmology.

The team determined that patients with early-stage or suspected glaucoma use approximately $623 per year in health care resources, while patients with end-stage disease consume approximately $2,511. The cost of medicine was responsible for one-third to half of the total direct cost to consumers.

"It is imperative that patients with glaucoma be well-monitored for changes in their disease," said Paul Lee, M.D., a glaucoma specialist at Duke University Eye Center and lead author on the study. "Our results prove what we've thought for a long time - that the disease gets more expensive as it worsens. With effective therapys at earlier stages, the progression of disease can be slowed or halted - saving both the patient and society from greater economic burden."

Glaucoma is a leading cause of blindness in the U.S., affecting an estimated 2.2 million adults, the scientists said. Experts anticipate the overall number of people living with glaucoma to rise as the number of elderly Americans increases. Glaucoma is a group of eye diseases that damage the cells and fibers of the optic nerve, interrupting the transmission of visual signals from the eye to the brain. The disease is believed to be caused by a level of intraocular pressure (IOP) that is too high, eventhough other mechanisms are likely to be involved since people can develop the disease and have a normal IOP. A number of people go undiagnosed during early stages of the disease because symptoms are virtually undetectable without an eye exam.

In their study, the team sought to determine whether the costs of managing glaucoma varied as the disease progressed in order to understand the relationship of patients' use of health resources to the severity of their disease.

They analyzed 151 randomly selected records of adult patients (average age was 66.3 years) with different severities of primary open-angle or normal tension glaucoma, as well as those suspected of having either glaucoma or ocular hypertension. They obtained records from 12 study sites throughout the U.S.

The scientists categorized patient records according to the severity of the patients' glaucoma. For each stage of severity, the scientists obtained economic data on the cost of the patients' use of eye care visits, visual field and other diagnostic testing, therapy procedures, low vision and other rehabilitation services, and prescribed medications. While the scientists based the medicine costs used in the study on wholesale prices, they said actual costs might be higher because consumers typically pay more than the wholesale cost.

"We know that for chronic diseases such as glaucoma, people don't use their medications as frequently as recommended by their physician," said Lee. "We took this into account in our study, but we suspect that the true costs of medicine use could be even greater than we found."

The scientists found that aggressiveness of glaucoma therapy increased over time with worsening of the disease, except for patients with end-stage glaucoma. That aggressiveness is likely to drop off in patients who have gone blind from glaucoma because therapy options for those patients may not offer significant benefits, said Lee.

"Since our data were collected, additional therapys have become available," Lee added. "However, these medications are fairly expensive. Ultimately, it may cost patients and society more to care for patients in earlier stages of the disease - but over the long-term, when managed correctly and effectively, glaucoma patients can retain more of their vision and therefore remain more productive with a presumably higher quality of life."
The research was funded by an unrestricted grant from Allergan, Inc., Irvine, CA.

Source: Duke Universtiy School of Medicine

Posted By: Mike




Did you know?
Treatments that delay the progression of glaucoma may significantly reduce the economic health burden on people with the disease and on the U.S. health system, according to a new study by scientists at Duke University Eye Center and elsewhere. Their findings appear in the January 9, 2006, issue of Archives of Ophthalmology.

Medicineworld.org: Treating Glaucoma Early

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology| Acute myeloid leukemia|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.